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RIASSUNTO 
Di recente, Dawson et al. hanno identificato e descritto un nuovo meccanismo 
d’azione di JAK2 in linee cellulari ematopoietiche ed in cellule CD34+ di un paziente 
affetto da mielofibrosi idiopatica (PMF) JAK2V617F mutato che prevede la sua 
traslocazione nucleare, la fosforilazione del residuo tirosinico 41 della proteina 
istonica H3 e la successiva esclusione dell’istone HP1a dalla cromatina con 
conseguente  disregolazione di diversi geni JAK2 correlati tra i quali LMO2. 
L’attivazione costitutiva di JAK2 causata da mutazioni puntiformi o da traslocazioni 
cromosomiche e’ un evento frequente nelle emopatie maligne con particolare 
riguardo alle sindromi mieloproliferative croniche (MPN) Philadelphia negative. Per 
documentare e confermare un possibile ruolo di JAK2 nel nucleo in presenza della 
mutazione V617F, abbiamo trasfettato la linea cellulare K562 con il costrutto  
pMSCV-Puro-JAK2V617F e confrontato con le K562 esprimenti il costrutto pMSCV-
Puro-wild-type (WT)-JAK2 mediante immunofluoresceza confocale (CIF) e Western 
Blot (WB). Per confermare i risultati in vitro abbiamo ricercato la possibile 
localizzazione nulceare di JAK2 in cellule di  midollo osseo  intero (BM) di 10 pazienti 
affetti da tutti i possibili sottotipi di MPN positivi per la mutazione V617F di JAK2 
[PMF n=3, policitemia vera (PV) n=3, trombocitemia essenziale (ET) n=4] e 5 
pazienti con MPN wild type (PMF n=2, ET n=3). Per identificare esattamente il tipo 
cellulare che esprimesse JAK2 nel nucleo, abbiamo selezionato mediante analisi 
citometrica (FACS) e raccolto con Cell sorting  4 popolazioni cellulari: CD34+, 
CD15+, CD41+ e CD71+ da cellule mononucleate totali di BM di 3 pazienti con MPN 
mutate (1 ET, 1 PV, 1 PMF). Le immagini ottenute al CIF e il WB su frazioni nucleari 
e citoplasmatiche hanno identificato JAK2 nucleare nelle K562 sebbene con un 
segnale piu’ forte solo in quelle esprimenti JAK2 mutato.  Questo ultimo dato e’ stato 
confermato all’analisi in  WB, dove le bande citoplasmatica e nucleare sono state 
identificate solo nelle K562 espimenti V617F JAK2 rispetto alla sola banda 
citoplasmatica delle cellule WT e delle cellule non trasfettate.  Nessuna differenza nel 
segnale nucleare e’ stata rilevata dopo l’aggiunta dell’inibitore dell’esporto nucleare 
leptomicina B suggerendo come l’esporto nucleare non sia coinvolto nella 
traslocazione nucleare della proteina JAK2. Abbiano rilevato un forte segnale 
nucleare della proteina JAK2 nel 3-5% di cellule mononucleate totali raccolte da BM 
di 10 su 10 pazienti con MPN JAK2V617F mutato. Abbiamo inoltre scoperto come 
nelle frazioni sortate, solo le cellule CD34+ dei pazienti con MPN JAK2 mutato, 
presentavano un forte segnale nucleare di JAK2 a differenza delle altre frazioni 
cellulari raccolte. Il dato e’ stato poi confermato all’analisi in WB sulle frazioni nucleari 
e citoplasmatiche isolate dalle cellule CD34+. Nessun segnale nucleare e’ stato 
identificato nelle frazioni cellulari differenziate in senso eritroide, granulocitario o 
megacariocitario o dalle rispettive colonie ottenute da tutti i pazienti esaminati (n=15). 
Abbiamo inoltre descritto come la presenza della mutazione di JAK2 comporti l’up-
regolazione del gene LMO2 nella K562 e in cellule CD34+ con JAK2V617F e inoltre 
come l’aggiunta di un potente inibitore selettivo di JAK2 (AG490) normalizzi 
progressivamente i livelli di LMO2 e riporti JAK2 dal nucleo al citoplasma in cellule 
K562. I nostri dati confermano e arricchiscono la recente scoperta di un meccanismo 
d’azione nucleare di JAK2 in linee cellulari emopoietiche. In questo studio 
descriviamo per la prima volta un ruolo nucleare di JAK2 in cellule di BM e in frazioni 
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CD34+ isolate da pazienti con tutte le forme di MPN JAK2 mutate ma non in quelle 
senza mutazione. Abbiamo inoltre documentato come in cellule differenziate e in 
colonie ottenute da tutti i pazienti non vi sia segnale nucleare di JAK2. Le modifiche 
strutturali della cromatina come conseguenza della traslocazione nucleare di JAK2 
andranno validate e meglio caratterizzate nei pazienti, dove ulteriori studi saranno 
condotti per identificare tutti gli effetti della proteina mutata nel nucleo, le altre 
proteine target e le modifiche sulla espressione dei geni. Questa intrigante scoperta 
rivela un nuovo scenario nella patogenesi delle sindromi mieloproliferative croniche e 
un nuovo modello per lo studio dell’emopoiesi maligna. 
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SUMMARY 
Recently, Dawson et al. identified a previously unrecognized nuclear role for 
JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of 
HP1a from chromatin and resulting in a disregulation of several JAK2-regulated 
genes such as LMO2 in haematopoietic cell lines and in one case on peripheral 
CD34+ cells from a JAK2V617F mutated primary myelofibrosis (PMF) patient. 
Activation of JAK2 by chromosomal translocations or point mutations is a frequent 
event in haematological malignancies particularly in Philadelphia negative 
myeloproliferative disorders (MPNs). To investigate and confirm a possible nuclear 
localization of JAK2 in presence of V617F mutation, we stably transfected K562 with 
pMSCV-Puro-JAK2V617F construct and compare with K562 expressing pMSCV-
Puro-wild type-(WT)-JAK2 and performed immunofluorescence and western blot 
analysis. To confirm the in vitro results we searched the possible nuclear localization 
of JAK2 in total BM of 10 patients affected by all types of JAK2V617F positive MPNs 
[PMF n=3, polycitemia vera (PV) n=3, essential thrombocythemia (ET) n=4] and 5 
patients with WT MPNs (PMF n=2 , ET n=3). To define which cells show nuclear 
JAK2, we selected by fluorescence activated cell sorting (FACS) 4 cell populations: 
CD34+, CD15+, CD41+ and CD71+ cells from total BM of 3 JAK2-mutated-MPNs (1 
ET, 1 PV, 1 early PMF). Confocal immunofluorescent images on nuclear and 
cytoplasmic fractions confirmed nuclear JAK2 in K562 although with the strongest 
nuclear signal in JAK2V617F expressing cells. This latter was also seen by western 
blot analysis which showed nuclear and cytoplasmic JAK2 only in JAK2V617F 
expressing K562 comparing with untransfected and WT cells. No differences in JAK2 
nuclear signal was observed by the addiction of the nuclear export inhibitor 
leptomycin B suggesting that export is not involved in nuclear JAK2 shuttling. We 
found a strong nuclear signal within the nuclei of 3-5% of mononucleated cells in 10 
of 10 JAK2 mutated patients but not in un-mutated cases. We found nuclear JAK2 in 
CD34+ cells but not in other cell populations of the 3 studied patients. Western blot 
performed on nuclear and cytoplasmic fractions of the JAK2V617FCD34+ cells 
confirmed the result. No nuclear JAK2 was detected in differentiated erythroid, 
granulocytic or megakaryocytic colonies obtained from all the studied patients 
(n=15). We also described how JAK2V617F up-regulates LMO2 in K562 and in 
JAK2V617F-positive CD34+ cells and that the selective JAK2 inhibitor AG490 
normalizes the LMO2 levels in V617F positive K562 and restores the cytoplasmic 
localization of JAK2. Our data corroborate the recent findings, obtained in 
hematopoietic cell lines, of a role of JAK2 in direct nuclear signaling. Furthermore we 
report, for the first time, a nuclear JAK2 in total BM and in sorted CD34+ cells of 
patients affected by all subtypes of JAK2 mutated MPNs and not in patients with WT 
diseases. We described also the absence of nuclear JAK2 in sorted mature cells and 
in differentiated colonies derived from the same patients. Possible chromatin 
modification due to JAK2 nuclear localization has to be better assessed in patients, 
where further studies are needed to understand the effects of mutated JAK2 in the 
nuclei, its target proteins and consequences on gene expression. This intriguing 
insight reveals a new scenario in the pathogenesis of malignant haematopoiesis and 
in myeloproliferative phenotype 
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INTRODUCTION 
Functional hallmarks of myeloid progenitors in myeloproliferative neoplasms 
The BCR-ABL-negative myeloproliferative diseases, which include polycythemia vera 
(PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), were 
recently renamed myeloproliferative neoplasms (MPNs).1  PV, ET and PMF are 
disorders of hematopoietic stem cells (HSCs) and early myeloid 
progenitors,2, 3 where myeloid progenitors are hypersensitive and/or independent of 
cytokines for survival, proliferation and differentiation. For instance, the majority of 
PV patients harbor erythropoietin (Epo)-independent erythroid colonies.4 Several 
intracellular anti-apoptotic pathways and molecules, such as STAT3, Akt or BclXL, 
are activated/induced constitutively in such MPN myeloid progenitors,5, 6, 7 along with 
hypersensitivity to insulin-like growth factor 1 (IGF-1), granulocyte macrophage 
colony-stimulating factor, interleukin 3 (IL-3), granulocyte colony-stimulating factor 
(G-CSF) or thrombopoietin (Tpo).8,9, 10, 11 Unlike many malignancies, where the 
INK4a locus is inactivated, erythroid progenitors from PV patients exhibit increased 
expression of the INK4a/ARF locus.12 
Mutations involved in PV, ET and PMF 
The acquired somatic JAK2 V617F mutation is harbored by the majority of PV 
patients and by more than 50% of ET and PMF patients.13, 14, 15, 16, 17	  Subsequent 
identification of exon 12 mutants of JAK2 in a minority of PV patients gave a 
molecular lesion to virtually all PV cases.18 Sequencing of the gene coding for the 
Tpo receptor (TpoR/c-Mpl) identified mutations in the juxtamembrane tryptophan 
residue W515 (W515L and W515K) in a low percentage of PMF and ET patients, the 
majority of which are JAK2 V617F-negative.19, 20 The W515 residue of TpoR is 
required to maintain the receptor inactive in the absence of ligand.21 All these 
mutations lead to constitutively active JAK–STAT pathway, especially JAK2, STAT5, 
STAT3, MAP kinase ERK1,2 and Akt.13, 16, 21	  Advancement over the past 3 years in 
the MPN research field has raised several major questions, such as: (i) What are the 
molecular bases for the significant differences in the in vivo phenotypes induced 
by JAK2 V617F and TpoR W515L? (ii) How can a unique somatic 
mutation, JAK2 V617F, be involved in the induction of three different diseases ET, 
PV or PMF? (iii) What mechanisms are responsible for the evolution of MPNs toward 
acute myeloid leukemia? (iv) What are the effects of JAK2 V617F and of the other 
JAK2 and TpoR mutants at the level of HSC? and (v) What preceding and 
subsequent (to JAK2 V617F) genetic events contribute to myeloproliferative 
diseases? Answers to these questions have begun to emerge. Gene dosage, as 
initially suggested by genotype/phenotype studies in patient cells,22 by retroviral bone 
marrow reconstitution studies23 and most recently probed in transgenic mice,24could 
be critically involved in inducing one or the other of the MPN phenotypes. It is 
fascinating that progenitors homozygous for the JAK2 V617F mutation occur in 
almost all PV patients, but very rarely in ET patients.25, 26 Although this can be seen 
as an argument in favor of the gene dosage hypothesis, other preceding or 
subsequent genetic changes might have an important function. Interestingly, host-
modifying influences might have a major part in establishing the disease 
phenotype.27 A screen for genetic variation within the genes coding for EpoR, TpoR, 
G-CSF receptor (G-CSFR) and JAK2 led to the discovery of three JAK2 single 
nucleotide polymorphisms that were significantly but reciprocally associated with PV 
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and ET, but not with PMF. Three additional JAK2 single nucleotide polymorphisms 
were uniquely associated with PV. Such single nucleotide polymorphisms, although 
not in the coding region of the genes, might affect the levels of gene transcription, 
regulation by other factors or possibly expression of other genes. 
 
Unknown effects of JAK2 V617F signaling in HSCs 
JAK2 V617F mutation was detected at the HSC and the common myeloid/lymphoid 
progenitor levels, it skews the HSC differential potential toward the erythroid lineage 
and gives a selective proliferative advantage to myeloid lineages.28, 29 The HSC 
compartment of PV and PMF patients was found to contain JAK2 V617F-positive 
long-term, multipotent and self-renewing cells, with a much higher proportion of 
mutated HSCs in PMF than in PV.30 It is not clear at this moment 
whether JAK2 V617F profoundly affects the biology of HSCs30 or whether it only 
gives a strong selection advantage past the HSC stage. A certain degree of 
heterogeneity exists between HSC subsets.31 HSCs exist in niches, some near 
osteoblasts and others near endothelial cells. Exactly where and in which HSC 
subset the JAK2 V617F mutation initially occurs might have a major impact on the 
subsequent disease phenotype. The JAK2 V617F mutation was present in 30–40% 
of splanchnic venous thrombosis patients (Budd–Chiari syndrome and portal vein 
thrombosis).32, 33,34, 35 A 'special' stem cell with hematopoietic/endothelial potential 
was suggested to be at the origin of splanchnic venous thrombosis, and it might 
harbor JAK2 V617F.36 A recent case report described a human allogeneic 
transplantation withJAK2 V617F-positive cells from such a splanchnic venous 
thrombosis donor (with one episode of JAK2 V617F-positive splanchnic venous 
thrombosis), but no MPN, to her HLA-matched sister with high-risk myelodysplastic 
syndrome (RAEB2).37 The recipient exhibited a JAK2 V617F burden similar to the 
donor immediately after transplant, but this burden decreased over time, and 7 years 
later, the recipient continues to be in remission and to exhibit low levels 
of JAK2 V617F positivity.37 These data suggest that, indeed, the JAK2 V617F 
mutation can occur in an HSC, but at least in the transplantation setting, this HSC 
has no proliferative advantage. A considerable amount of data suggests that in 
addition to the presence of theJAK2 V617F mutation, preceding or subsequent 
genetic events might be necessary for developing the MPN disease. First, in certain 
MPN patients, the clonality of expanded myeloid progenitors is found to be larger 
than the JAK2 V617F clone, with the acquisition of JAK2 V617F being a late genetic 
event.38 Second, acute myeloid leukemia cases developed inJAK2 V617F-positive 
patients can occur with leukemic blasts not harboring JAK2 V617F.39 Third, Epo-
independent colonies might not always harbor the JAK2mutation in patients with 
the JAK2 V617F mutation.40 Such preceding or subsequent events could be 
associated differently with the three diseases, namely ET, PV and PMF. 
 
The signaling space 
Molecular cell biology textbooks list eight major signaling pathways that control gene 
expression that are linked to eight classes of cell surface receptors: cytokine 
receptors, receptor tyrosine kinases, receptors for transforming growth factor (TGF)-
, Wnt, Hedgehog, tumor necrosis factor (TNF)- , Notch (Delta) and G-protein-
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coupled receptors.41 Nuclear and corticoid receptor pathways, as well as integrin 
signaling, complete the picture of intracellular cell signaling. In several paper it has 
been well described that aberrant signaling occurs in MPNs through some of the 
listed pathways, such as cytokine receptors, receptor tyrosine kinases, TGF- and 
TNF- . It is not clear whether aberrant signaling in MPNs is simply due to the 
constitutive nature of signaling induced by mutated JAK2 or TpoR, or whether 
specific cross-talk events occur to other pathways that might confer specificity to 
JAK2 V617F versus JAK2 signaling. It is important to recognize from the outset that 
the experimental systems used by signal transduction research, such as 
phosphorylation studies, co-immunoprecipitation, gene expression and determination 
of protein localization, may not be able to identify subtle relative changes, such as 
kinetics and amplitude differences, between signals engaging generic pathways that 
are redundantly triggered by many stimuli. Such subtle quantitative differences might, 
however, be crucial for the disease phenotypes in vivo. That is the reason why 
genetics, in vivo models, results obtained with inhibitors and data derived from 
primary cells, must be taken into account to draw a picture describing aberrant 
signaling in MPNs. 
 
Constitutive signaling and kinase activity of JAK2 V617F 
The mammalian genome codes for four Janus kinases (JAKs), JAK1, JAK2, JAK3 
and Tyk2. On the basis of homology, JAKs share seven JAK homology domains 
(JH), denoted as JH1–JH7. From the C to the N terminus, JH1 represents the kinase 
domain, JH2 the pseudokinase domain, JH3 and JH4 contain an SH2-like domain 
and linker regions, whereas JH5–JH7 contain a FERM (band 4.1, ezrin, radixin, 
moesin) domain42, 43 (Figure A).  
 
 
Figure A. Schematic illustration of Janus kinase (JAK)2 and the different JAK homology 
(JH) domains. The V617F mutation occurs in the pseudokinase domain rendering the 
kinase domain constitutively active. Exon 12 mutations, such as K539L, occur in the 
linker region between the JH3 and JH2 domains. Tyrosine residues that can be 
phosphorylated are depicted by their single letter. See text for details. 
 
JAKs have been proposed to have a bipartite structure and the N terminus is 
required for binding to receptors, chaperoning and stabilizing them at the 
surface,44, 45, 46, 47 whereas the kinase domain is absolutely crucial for signaling. The 
pseudokinase domain precedes the kinase domain, and because of sequence 
differences at key residues required for catalysis, it cannot transfer phosphate and 
thus is catalytically inactive.42 Nevertheless, the pseudokinase domain is structurally 
required for the response of JAKs to cytokine receptor activation and for inhibiting the 
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basal activity of the kinase domain.48, 49 The V617F mutation occurs in the 
pseudokinase domain, leading to constitutive activation of the kinase domain (Figure 
A). Although no X-ray crystal structure of full-length JAK2 exists, modeling has 
suggested that the pseudokinase domain of JAK2 maintains the kinase domain 
inactive in the basal state.50 Thus, the V617F mutation is expected to relieve the 
inhibitory effect of JH2 on JH1 and to lead to basal kinase activity. The homologous 
V617F mutations in JAK1 and Tyk2 also lead to constitutive activation,51 which 
strongly supports this model. Activating mutations in the pseudokinase domain of 
JAK1 at the homologous V658 position or at neighboring residues have been 
reported in 20% of patients with T-acute lymphoblastic leukemia.52, 53 In transiently 
transfected JAK2-deficient cells, such as the -2A human fibrosarcoma cell 
line,54 JAK2 V617F expression leads to constitutive activation of STAT5 and STAT3 
signaling. In such transient transfection experiments, JAK2 V617F is constitutively 
tyrosine phosphorylated at the activation loop Y1007. Co-transfection of wild-type 
JAK2 reduces signaling by JAK2 V617F, presumably due to competition for an 
interaction partner, such as a cytokine receptor,13 but does not prevent constitutive 
phosphorylation of JAK2 V617F.16 To investigate the catalytic activity of JAK2 V617F 
mutation, kinase assays have been performed on GST fusion proteins. In COS7 
overexpression conditions, when compared with wild-type JAK2, the JAK2 V617F 
mutated protein exhibits enhanced basal kinase activity on a reporter GST fusion 
protein containing the sequence of the activation loop of JAK2 containing tyrosine (Y) 
1007.17, 55 The kinase activity was clearly increased, but it appeared to be weak. In 
stably transfected Ba/F3 cells, JAK2 V617F also exhibits enhanced kinase activity on 
the same Y1007-containing GST fusion protein, but the levels of activation were also 
small (C Pecquet et al., unpublished results). This is very different from BCR-ABL or 
other fusion proteins such as TEL-JAK2, where the kinase domain alone is 
oligomerized and activated by a fused exogenous oligomeric domain. In contrast, the 
kinase domain of JAK2 V617F is expected to maintain most of the negative 
regulatory intramolecular interactions that normally limit kinase domain activation. 
 
JAK2 V617F and cytokine receptors 
The FERM domain of JAKs is responsible for appending JAKs to cytokine receptors. 
Cytokine receptors contain in the cytosolic juxtamembrane region a proline-rich 
sequence, usually PxxPxP, denoted as Box 1, located 10–15 amino acid residues 
downstream of the TM domain, and further down 50–60 amino acid residues 
downstream of the TM domain, a sequence composed of hydrophobic and charged 
residues denoted as Box 2.56 JAK2 binds to the region of EpoR that encompasses 
cytosolic residues of Box 1, Box 2 and also most of the residues between these 
boxes.44, 56 Interaction between JAK2 and EpoR or TpoR is disrupted by a point 
mutation (Y114A) in the FERM domain.47 Expression of the double-mutant JAK2 
V617F Y114A in Ba/F3-EpoR cells did not lead to constitutive signaling through 
STAT5 or to autonomous growth,57 suggesting that the V617F mutation does not 
suffice for activation in the absence of the assembly between the JAK2 V617F and a 
cytokine receptor. It can be noted that members of the JAK family are localized to 
membranes through recruitment by cytokine receptors, whereas mutations such as 
Y114A lead to cytosolic localization.58 Furthermore, a mutation in the pseudokinase 
domain of JAK2 was identified (Y613 to glutamic acid, Y613E), which promotes 
constitutive activation only when JAK2 is in complex with the EpoR.59 This result 
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suggests that in the absence of an association with a cytokine receptor, JAK2 is 
locked into an inactive state and that receptor binding through the FERM domain is 
important for activation.59 Another argument supporting the notion that binding to a 
cytokine receptor is important for the activity of the V617F mutant arises from the 
lack of activation of JH2–JH1 fusion proteins where the V617F mutation was 
introduced in the JH2 sequence.60 The low basal activity of JH1 was shown to be 
suppressed by fusion with JH2.49, 61 However, the presence of the FERM–SH2 
domains is required for the activation effect exerted by the V617F mutation. JAK2 is 
crucial for signaling by EpoR62 and TpoR,63, 64 participates in signaling by G-
CSFR65, 66 (Figure B) and also mediates signaling by the IL-3/IL-5/granulocyte 
macrophage colony-stimulating factor family of cytokines, as well as by several type-
II cytokine receptors, such as interferon-  receptor 267. Given that MPNs mainly 
affect the erythroid, the megakaryocytic and the granulocyte lineages, as stated 
before, complexes between JAK2 V617F and EpoR, TpoR and G-CSFR may explain 
cytokine hypersensitivity and independence in these diseases (Figure B). 
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Figure B. Model of constitutive (ligand-independent) signaling induced by JAK2 V617F through 
erythropoietin receptor (EpoR), thrombopoietin receptor (TpoR) and granulocyte colony-stimulating 
factor receptor (G-CSFR). (i) Janus kinase 2 (JAK2) is the main JAK used by EpoR and TpoR, but 
i	  
ii	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JAK1 is also used physiologically by G-CSFR. Primarily, EpoR and TpoR are expected to be bound by 
JAK2 V617F, whereas G-CSFR is expected to be in complex with JAK2 V617F at high JAK2 V617F 
levels, i.e., in homozygous JAK2 V617F situations. Scaffolding of JAK2 V617F on the cytosolic tails of 
cytokine receptors leads to the enhanced activation of JAK2 V617F and downstream signaling through 
STATs, MAP kinase, PI-3-kinase (PI3K) and Akt. SOCS proteins are expected to engage both EpoR 
and activated wild-type JAK2, leading and down-modulation of JAK2 activity; the EpoR–JAK2 V617F 
complex appears to escape the down-modulation activity of SOCS3. (ii) Cytokine receptors that are in 
complex with JAK2 V617F are hypersensitive to their ligands for signaling. Cytokine binding to 
receptors coupled to wild-type JAK2 induce transient physiologic signals, leading to survival, 
proliferation and differentiation of myeloid progenitors. In contrast, receptors coupled to JAK2 V617F 
respond to lower levels of ligand, and are constitutively signaling after ligand withdrawal. It is not 
known whether dimeric receptor complexes, where one monomer is coupled to JAK2 V617F and the 
other to wild-type JAK2, are also hypersensitive to ligand or constitutively active. 
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EpoR and MPNs 
EpoR functions as a preformed dimer on the cell surface, which upon cytokine 
binding undergoes a conformational change that triggers the activation of the 
receptor pre-bound JAK2.68, 69 This involves a rotation of the receptor monomers 
within the dimer,70 which is transmitted to JAK2 by switch residues, that is W258 in 
the juxtamembrane domain of EpoR.69 Current data suggest that JAK2 V617F can 
scaffold on the cytosolic domain of EpoR and induce Epo-independent signaling, 
possibly by phosphorylating key cytosolic tyrosine residues on EpoR, which leads to 
strong STAT5 activation.71 Early on after the identification of JAK2 V617F, the need 
for a co-expressed type I dimeric cytokine receptor for constitutive signaling by JAK2 
V617F provoked a controversy, which in the end led to a model of how dimeric 
receptors might actually promote JAK2 V617F activation. One study by Levine et 
al.16 reported that JAK2 V617F readily induced autonomous growth in Ba/F3 cells 
engineered to express the EpoR (Ba/F3 EpoR cells), but not in parental Ba/F3 cells. 
In contrast, the study by James et al.13 had shown that JAK2 V617F could induce 
autonomous growth in both Ba/F3 EpoR and parental Ba/F3 cells. This controversy 
(also described in Ihle and Gilliland72) was solved by carefully assaying the levels of 
JAK2 V617F transduction: at low levels, co-expression of a type I cytokine receptor 
was necessary for autonomous growth, whereas at higher levels JAK2 V617F alone 
induced autonomous growth, most likely by binding to an endogenous cytokine 
receptor, such as the IL-3-receptor -subunit.60 It is not clear whether other 
receptors—besides dimeric type I—could also promote signaling by low levels of 
transduced JAK2 V617F (Figure B(ii)). Nevertheless, given that EpoR is a dimer in 
the absence of ligand, an insightful model was proposed by Harvey Lodish. In it, 
dimerization of JAK2 V617F by such a receptor is considered necessary for the 
activation of JAK2 V617F signaling, and the subtle V617F mutation promotes kinase 
activation when JAK2 is scaffolded on an inactive receptor dimer (Figure 
B(i)).71 Given that in MPNs the three lineages affected are controlled by the three 
type I dimeric cytokine receptors, EpoR, TpoR and G-CSFR, the model that JAK2 
V617F mainly functions as a transforming kinase in association with these receptors 
is very plausible. EpoR signals mainly by JAK2–STAT5 and PI-3–kinase/Akt (Figure 
B(i)) pathways. It is a weak activator of MAP kinase and of STAT3,73 as it does not 
contain a consensus site for STAT3 binding, whereas several phosphorylated 
tyrosine residues (Y343, Y401, Y429 and Y431) can bind STAT5 and are required for 
maximal STAT5 activation.74, 75 A consequence of STAT5 activation is induction of 
the anti-apoptotic BclXL protein expression,76 which is constitutively expressed in PV 
erythroid progenitors.7 The connection of EpoR with the PI-3–kinase pathway is 
accomplished by specific tyrosine residues, that is Y479, which appears to bind the 
regulatory subunit p85.77, 78 PI-3–kinase and Akt activations are critically involved in 
erythroid differentiation,79 possibly by the involvement of the transcription factor 
Forkhead family, FKHRL1.80 Another mechanism appears to be the phosphorylation 
of S310 of GATA1.81 Thus, scaffolding of an activated JAK2 to EpoR is predicted to 
activate the JAK2–STAT5 and PI-3–kinase/Akt pathways and stimulate proliferation 
and differentiation of erythroid progenitors. 
 
EpoR and exon 12 JAK2 mutations 	  
Patients with exon 12 JAK2 mutations, such as JAK2 K539L, exhibit an 
erythrocytosis phenotype, without pathology changes to megakaryocytes typical for 
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MPNs.18 Unlike the uniqueness of the point mutation that generates JAK2 V617F, 
several deletions and insertions were noted in the case of exon 12 mutations.18, 82 An 
attractive hypothesis is that exon 12 mutants of JAK2 favor interaction with EpoR 
over TpoR or G-CSFR, although a mechanistic basis for such a preference has yet to 
be found. Modeling of JAK2 suggests that the K539L falls in a loop in the linker 
region between the SH2 and the JH2 domain (Figure A), which would be placed in 
space quite close to the loop represented by 4– 5 where V617 is located. 
 
TpoR and MPNs 
TpoR is coupled to and activates both JAK2 and Tyk2,64, 83, 84 which appear to have 
comparable affinities for the receptor juxtamembrane domain and to promote cell 
surface traffic of the receptor to a similar extent.47 However, JAK2 is much more 
effective than Tyk2 in transmitting the signals of the receptor.47,64 TpoR activates 
JAK2, STAT5 and PI-3–kinase/Akt,85 but in contrast to EpoR, it is a very strong 
activator of Shc, of the MAP kinase pathway and of STAT3 (Figure 
B(i)).83, 86, 87, 88, 89, 90 It is interesting that the first consequence of expressing the JAK2 
V617F (at lower than physiologic levels in the transgenic model) mutation is to 
promote platelet formation.24 Bipotential megakaryocyte–erythroid progenitors appear 
to be stimulated to engage on the platelet formation by STAT3 activation, whereas 
STAT5 activation favors erythroid differentiation programs.91 STAT5 emerged as a 
critical factor for lineage commitment between erythroid and megakaryocytic cell 
fates. Depletion of STAT5 from CD34(+) cells in the presence of Tpo and stem cell 
factor favors megakaryocytic differentiation at the expense of erythroid 
differentiation.91 Overexpression of an activated form of STAT5 impaired 
megakaryocyte development favoring erythroid differentiation at the expense of 
megakaryocyte differentiation.91 Thus, at low levels of expression, JAK2 V617F might 
only activate STAT3, which might suffice for platelet formation. At higher expression 
levels, coupling to both TpoR and EpoR will lead to STAT5 activation, and this would 
favor the erythroid program. It is not clear at this point whether the PV phenotype is 
exclusively the result of EpoR activation or whether the pathologic activation of TpoR 
might also contribute to the PV phenotype. It is interesting to note that 
overexpression of TpoR in certain animal models led to an expansion of the erythroid 
compartment.92 The SH2 and PH (pleckstrin homology domain) adapter protein Lnk 
was shown to not only bind to phosphorylated tyrosine residues of both TpoR and 
EpoR but also to exert a negative role on signaling by these receptors.93, 94 It is not 
known whether the defects in this negative regulatory mechanism are operating in 
MPNs. Co-expression of JAK2 V617F and TpoR in Ba/F3 cells leads to down-
modulation of TpoR, most likely due to internalization and down-modulation seen 
after excessive activation of cytokine receptors (J Staerk, C Pecquet, C Diaconu and 
SN Constantinescu, unpublished observations). This is consistent with early studies 
that have identified a maturation defect and down-modulation of cell surface TpoR in 
platelets and megakaryocytes from MPN patients.95 More recently, an inverse 
correlation was reported between the burden of JAK2 V617F and the levels of cell 
surface TpoR on platelets.96 Although these results suggest that JAK2 V617F may 
contribute to the down-modulation of TpoR, several patients with MPNs in the 
absence of JAK2 V617F also exhibited down-modulated TpoR. Such down-
modulation is not seen for EpoR. TpoR is a long-lived receptor at the cell 
surface47 and recycles,97 which is not the case for EpoR. Further experiments are 
necessary to follow up on the original observation of TpoR down-modulation in 
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MPNs, which may be due to traffic alterations, excessive internalization and 
degradation or decreased protein synthesis. Several mutations in Mpl induce myeloid 
malignancies. A mutation in the transmembrane domain of Mpl, S505N, constitutively 
activates the receptor98and has been discovered in familial ET.99 The S505N 
mutation in the transmembrane domain is expected to promote constitutive activation 
due to polar interactions between the asparagines that replace the natural serine. As 
stated earlier, mutations in Mpl at W515 induce severe MPNs with 
myeloprofibrosis.19, 20 W515 mutations activate constitutive signaling by the receptor 
because W515 belongs to an amphipathic juxtamembrane helix (RWQFP in the 
human receptor), which is required for maintaining the un-liganded receptor in the 
inactive state. Another activating mutation was recently described for TpoR, where a 
threonine residue in the extracellular juxtamembrane region (located symmetrically 
from the W515 mutation on the N-terminal side of the transmembrane domain) is 
mutated to alanine (T487A) in a non-Down's syndrome childhood acute 
megakaryocytic leukemia.100 In bone marrow transplantation assays, this Mpl T487A 
also induces a severe myeloproliferative disease, close to the phenotype induced by 
TpoR W515L.100 Juxtamembrane mutations such as W515L/K or T487A may not 
only promote active dimeric conformations, but they could also induce receptor 
conformational changes by changing crossing angles between receptor monomers, 
whereas the S505N highly polar mutation in the transmembrane domain is predicted 
to stabilize an active dimeric conformation of the receptor. It will be interesting to test 
side by side in bone marrow transplantation experiments the effects of S505N, 
W515L and T487A mutations and to assess whether indeed the phenotype of the 
TpoR S505N mutation would be milder. 
 
G-CSFR and MPNs 
Bone marrow transplanted mice with HSCs expressing JAK2 V617F present not only 
an MPN phenotype, with low Epo, as predicted, but also with low G-CSF serum 
levels, suggesting that constitutive activation of G-CSFR occurs in these mice.101 G-
CSFR uses both JAK1 and JAK2 for signaling.65, 66 JAK2 V617F may affect G-CSFR 
signaling with less efficiency than for EpoR and TpoR, as JAK1 may be the key JAK 
for G-CSFR. This is perhaps the reason why the granulocytic lineage is affected to a 
lower extent in MPNs, when compared with the erythroid and megakaryocytic 
lineages, especially at low levels of JAK2 V617F. Activation of the G-CSFR JAK2 
V617F complexes may lead to enhanced numbers of granulocytes, constitutive 
activation of granulocytes (with release of enzymes) as well as interactions with 
platelets, which would contribute to thrombotic complications. It is not clear whether 
leukocytosis, which is seen in certain MPN patients and which appears to be 
associated with certain complications or evolution toward leukemia,102 may be due to 
the pathologic activation of G-CSFR by JAK2 V617F. Granulocytes from patients with 
MPNs presented altered gene expression promoted by JAK2 V617F expression and 
confirmed a recapitulation of cytokine receptor signaling, resembling profiles of 
granulocytes activated by G-CSF.103 Similar to TpoR, G-CSFR activates STAT3 and 
MAP kinase pathways, in addition to the JAK2–STAT5 and PI-3–kinase/Akt 
pathways. It can be noted that for this receptor, a very delicate balance has been 
identified between the activation of STAT3, required for differentiation and inducing a 
stop in cell growth (necessary for differentiation), and STAT5, which promotes 
proliferation.102 Binding of SOCS3 through its SH2 domain to a phosphorylated 
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tyrosine residue in the receptor's cytosolic end specifically downregulates STAT5 
signaling. Deletion of the cytosolic region, which contains the binding site for SOCS3, 
leads to enhanced STAT5-to-STAT3 signaling ratio,102 and this is associated with 
evolution toward acute myeloid leukemia of patients with severe congenital 
neutropenia. G-CSFR activation might synergize with other mechanisms and 
promote the mobilization of CD34(+) stem cells and progenitors from the bone 
marrow to the periphery. Interestingly, an increased number of circulating CD34(+) 
cells in MPN patients has been observed, and they exhibit granulocyte activation 
patterns similar to those induced by the administration of G-CSF.104 The release of 
CD34(+) cells is generally due to a combination of increased levels of 
proteases105 and especially due to the downregulation of the CXCR4 receptor on 
CD34(+) cells.106 An altered SDF-1/CXCR4 axis was demonstrated in PMF patients 
with CD34(+) cells in the periphery.107 These findings are supported by the rapid 
mobilization of CD34(+) cells with AMD3100, a CXCR4 antagonist.108 
 
Tyrosine phosphorylation pattern of JAK2 V617F 
JAK2 V617F is constitutively tyrosine phosphorylated. However, besides Y1007 in 
the activation loop, which is crucial for activation,109 it is not known whether other 
phosphorylated tyrosines overlap with those phosphorylated in the wild-type JAK2. It 
can be noted that, JAK2 contains multiple tyrosine residues, of which at least 14 can 
be phosphorylated110 (Figure A). Some of these tyrosine residues exert positive 
(Y221) and other negative (Y119, Y570) effects on signaling by JAK2.111, 112, 113 Y813 
is a recruitment site for SH2-containing proteins,114 such as SH2B, which can 
promote homodimerization of JAK2.115 In theory, the constitutive activation of JAK2 
V617F might promote a different pattern of phosphorylated tyrosines from that of 
wild-type JAK2. 
 
STAT activation and MPNs 
A hallmark of MPNs is constitutive or hypersensitive activation of the STAT family of 
transcription factors in myeloid precursors. As mentioned, the expressions of JAK2 
V617F, TpoR mutants or exon 12 JAK2 mutants lead to constitutive STAT5 and 
STAT3 activation in various systems.18, 116 As a function of the MPN disease type, 
one or the other of the STATs was suggested to be predominantly activated by JAK2 
V617F. For example, in myelofibrosis, JAK2 V617F expression in neutrophils is 
associated with the activation of STAT3 but apparently not with that of STAT5.117 In 
another study, in bone marrow biopsies and irrespective of JAK2 V617F, PV patients 
exhibited high STAT5 and STAT3 phosphorylation and ET patients exhibited high 
STAT3, but low STAT5 phosphorylation, whereas myelofibrosis patients exhibited 
low STAT5 and STAT3 phosphorylation.118 Thus, constitutive activation of the 
STAT5/STAT3 signaling appears to be a major determinant of MPNs, irrespective of 
the particular JAK2 or receptor mutation. Furthermore, STAT3 activation by IL-6 has 
been shown in a murine model system to hold the potential to experimentally induce 
MPN. Mice homozygous for a knockin mutation in the IL-6 receptor gp130 
(gp130(Y757F/Y757F)), which leads to gp130-dependent hyperactivation of STAT1 
and STAT3 develop myeloproliferative diseases with splenomegaly, 
lymphadenopathy and thrombocytosis. gp130(Y757F/Y757F) is hyperactive owing to 
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impaired recruitment of negative regulators such as SOCS3 and the SHP2 
phosphatase.119,120 The hematological phenotype disappeared when the knockin 
mice were crossed with heterozygous Stat3(+/-) mice.121 Thus, the threshold of 
STAT3 signaling elicited by IL-6 family cytokines may have an important function in 
the myeloid lineage and may contribute to the development of MPN. 
 
SOCS3 and JAK2 V617F 
Suppressors of cytokine signaling (SOCS) proteins negatively regulate cytokine 
receptors and JAK–STAT signaling. There are eight members of the SOCS/CIS 
(cytokine-inducible SH2-domain-containing protein) family, namely SOCS1–SOCS7 
and CIS. Each SOCS molecule contains a divergent N-terminal domain, a central 
SH2 domain, and a C-terminal 40 amino acid domain known as the SOCS 
box.122 CIS/SOCS proteins are supposed to function as E3 ubiquitin ligases and 
target proteins bound to the SOCS N terminus, such as active JAKs, as well as 
themselves for proteasome-mediated degradation.122 SOCS1 and SOCS3 can also 
inhibit the catalytic activity of JAK proteins directly, as they contain a kinase inhibitory 
region (KIR) that targets the activation loop of JAK proteins. SOCS proteins bind 
receptors and then target the activation loop of JAKs for inhibition by KIR and SH2 
interactions.122 SOCS3 is known to strongly down-modulate EpoR signaling.123 JAK2 
V617F appears not to be downregulated by SOCS3, possibly due to continuous 
phosphorylation of SOCS3, which can impair its E3 ligase activity.124 Constitutive 
tyrosine phosphorylation of SOCS3 was also reported in peripheral blood 
mononuclear cells derived from patients homozygous for the JAK2 V617F 
mutant.124 Taken together, a model was proposed in which JAK2 V617F may escape 
physiologic SOCS regulation by hyperphosphorylating SOCS3. It would be important 
to also determine whether exon 12 mutants of JAK2 are able to overcome down-
modulation by SOCS3. Furthermore, one of the two tyrosine residues in the C 
terminus of SOCS3 that become phosphorylated upon ligand-activated cytokine 
receptors interacts with the Ras inhibitor p120 RasGAP.125 This leads, in the case of 
IL-2 signaling, to sustained ERK activation, whereas the JAK–STAT pathway is 
down-modulated.125Whether part of the sustained ERK activation detected in cells 
transformed by JAK2 V617F may involve complexes of degradation-resistant SOCS3 
and p120 RasGAP is yet to be determined. 
 
Other JAK2 mutations activate JAK2 
Substitution of pseudokinase domain residue V617 by large non-polar amino acids 
causes activation of JAK2.126 Saturation mutagenesis at position 617 of JAK2 
showed that, in addition to V617F, four other JAK2 mutants, V617W, V617M, V617I 
and V617L, were able to induce cytokine independence and constitutive downstream 
signaling. However, only V617W induced a level of constitutive activation comparable 
with V617F, and like V617F it was able to stabilize tyrosine-phosphorylated 
SOCS3.126 Also, the V617W mutant induced a myeloproliferative disease in bone-
marrow-reconstituted mice, mainly characterized by erythrocytosis and 
megakaryocytic proliferation. Although JAK2 V617W would predictably be pathogenic 
in humans, the substitution of the Val codon, GTC, by TTG, the codon for Trp, would 
require three base pair changes, which makes it unlikely to occur. Therefore, codon 
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usage and resistance to SOCS3-induced down-modulation are two mechanisms that 
might explain the uniqueness of JAK2 V617F in MPNs. 
 
 
ANIMAL MODELS OF MPNs 
 
JAK2 mutants 
Mouse bone marrow reconstitution experiments with HSCs retrovirally transduced 
with JAK2 V617F resulted in strain-dependent myeloproliferative disease 
phenotypes. In these models, JAK2 V617F is expressed at 10-fold higher than 
endogenous levels. In C57Bl6 mice, JAK2 V617F induces erythrocytosis, and in 
some animals myelofibrosis, although most reconstituted mice remain alive several 
months, and in some the erythrocytosis regresses; in Balb/c mice, the phenotype is 
more severe with erythrocytosis being followed by myelofibrosis.13, 23, 127 Only very 
rarely, at low transduction levels, was a thrombocytosis phenotype observed, which, 
together with initial studies on primary patient cells,22 led to the suggestion that gene 
dosage may be important for a particular phenotype to develop.23 This hypothesis 
has been supported by studies in transgenic mice in which the expression of the 
JAK2 V617F was carefully regulated.24 When JAK2 V617F levels were lower than 
endogenous JAK2 levels, an ET phenotype was obtained. When levels of JAK2 
V617F were similar to those of endogenous wild-type JAK2, a PV-like phenotype was 
developed. Interestingly, upon development of the PV phenotype, a selection for 
higher levels of JAK2 V617F occurs, up to 5- to 6-fold higher than the endogenous 
JAK2 levels, which is not the case for the ET phenotype.24 This indicates positive 
selection for JAK2 V617F expression in PV progenitors, a phenomenon that can be 
detected in stably transfected Ba/F3 cells.51 In addition overexpression of several 
non-mutated JAK proteins, including JAK2, was shown to promote hematopoietic 
transformation to cytokine independence.128 The phenotype induced by exon 12 
mutants of JAK2 is more restricted to erythrocytosis, without the abnormal 
megakaryocyte clusters seen in the classical MPNs.18 These in vivo data indicate 
that a difference must exist between signaling by JAK2 V617F and exon 12 JAK2 
mutants. 
 
Mpl (TpoR) mutants 
The phenotype induced by TpoR W515L is different than that induced by JAK2 
mutants, in that it is much more severe, with initial myeloproliferation, marked 
thrombocytosis, splenomegaly and myelofibrosis, and is established within 20–30 
days after reconstitution.19 At least one other mutation at W515 was identified in 
patients with PMF and ET, that is W515K.20 W515 is located in an amphipathic motif 
(RWQFP) at the junction between the transmembrane and cytosolic domains. This 
motif is required to maintain the un-liganded TpoR in an inactive state. Given that a 
W515A mutation is also active,21 it is not surprising that such different residues (Leu 
and Lys) are found in active TpoR mutants. We predict that other W515 mutations 
will be found in patients, as the loss of a Trp (W) residue is responsible for activation. 
	  17	  
The striking difference in severity and histopathology between the phenotypes 
induced by JAK2 V617F and Mpl 515 mutants is hard to understand when standard 
phosphorylation studies are performed on cell lines, such as Ba/F3 cells, where the 
same redundant pathways are activated by both JAK2 V617F and Mpl 515 mutants. 
Interestingly, deletion of the amphipathic motif ( 5TpoR) that contains W515 or the 
mutation of either the lysine K514 (R514 in the human receptor) or the W515 in this 
motif to alanine leads to constitutive JAK2 and STAT activation and colony formation 
in primary cells and hypersensitivity to Tpo.21 In hematopoietic cells transformed by 
5TpoR (amphipathic motif deleted) or TpoR W515A, we noted enhanced STAT5 
and MAP kinase activation in the absence of Tpo, and high levels of activation of 
STAT5, STAT3 and MAP kinase pathways on Tpo treatment.21 Such TpoR mutants 
do not down-modulate cell surface levels of TpoR,21 unlike TpoR in complex with 
JAK2 V617F, which is down-modulated (J Staerk et al., unpublished observations). It 
is therefore tempting to speculate that prolonged activation of MAP kinase and 
STAT3 might be a distinct feature of TpoR W515 mutants, whereas JAK2 V617F, 
which couples not only to TpoR but also to other cytokine receptors expressed in 
myeloid progenitors, would generate a weaker or different signal. Taken together, 
these data suggest that some level of signaling specificity must exist, which would 
make the excessive activation of TpoR through JAK2 V617F qualitatively different 
from that induced by W515 mutations. Understanding this difference at the signaling 
level will be of utmost importance. 
 
Lessons from JAK2 inhibitors 
An impetus driving the search for mutations in JAK2 was given by the finding that a 
JAK2 inhibitor, AG490, as well as inhibitors of the PI-3-kinase, was able to inhibit the 
Epo-independent colony formation from myeloid progenitors of PV 
patients.13, 129 After the discovery of JAK2 V617F, several selective JAK2 inhibitors 
have been developed. These inhibitors do not discriminate between the wild-type and 
the mutant JAK2, but show specificity for JAK2 when compared with JAK1, JAK3, 
Tyk2 and other tyrosine kinases. As the expression of JAK2 V617F leads to 
constitutive activation and hypersensitivity to cytokines (Figure B(ii)), such inhibitors 
might inhibit pathologic hematopoiesis at lower doses than those that would suppress 
normal hematopoiesis. One such molecule, TG101209, was able to inhibit 
proliferation of both JAK2 V617F- and TpoR W515L/K-expressing hematopoietic 
cells.130 It may be recalled that TpoR W515-mutated proteins are expected to 
constitutively activate the wild-type JAK2. Another selective JAK2 inhibitor, 
TG101348, was effective in a murine model of MPN induced by JAK2 V617F131 and 
inhibited the engraftment of JAK2 V617F-positive HSCs and myeloid progenitors in a 
bioluminescent xenogeneic transplantation assay.132 Importantly, the inhibitor 
decreased GATA1 expression and phosphorylation of GATA1 at S310 and, as 
expected, STAT5 activation. These signaling events might be associated with 
erythroid-skewing of JAK2 V617F-positive progenitor differentiation, as 
phosphorylation at GATA1 S310 was shown to be important for erythroid 
differentiation.81 GATA1 is absolutely required for erythroid and megakaryocyte 
formation.133, 134 Although both EpoR and GATA1 are crucial for erythroid 
differentiation, this phosphorylation event, which depends on PI-3-kinase and 
Akt,81 appears to be the only one described where a direct EpoR downstream signal 
affects GATA1. 
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CROSS-TALK: JAK2 V617F AND OTHER PATHWAYS 
 
JAK2 V617F and other tyrosine kinases 
Tyrosine kinase receptors have been suggested to contribute to the pathogenesis of 
PV. In patients with PV, circulating erythroid progenitor cells are hypersensitive to 
IGF-1 and this effect requires the IGF-1 receptor.10, 135Expression of JAK2 V617F in 
Ba/F3 cells renders the cells responsive to IGF-1 at doses where parental Ba/F3 
cells are unresponsive.51 After selection for autonomous growth, these Ba/F3 JAK2 
V617F cells acquire the ability to respond to IGF-1 by further tyrosine 
phosphorylation of the mutant JAK2 and of STAT5 and STAT3. Which 
adaptor/signaling protein mediates this cross-talk is not clear, but it might be relevant 
for the hypersensitivity of PV erythroid progenitors to IGF-1. 
Treatment with imatinib, an inhibitor of the Abl, c-KIT and PDGF receptor kinase, 
leads to minimal responses in PV, but nevertheless some rare patients achieve 
remission and a decrease in the JAK2 V617F allele burden.136 Imatinib exerts a 
dose-dependent growth inhibitory effect on factor dependent cell paterson (FDCP) 
cells expressing JAK2 V617F, most likely by interrupting the cross-talk between 
JAK2 V617F and c-KIT.137 Thus, this study predicts that in PV patients where 
imatinib exerts benefic effects, pathologic signaling occurs through c-KIT. 
Src tyrosine kinases have also been suggested to contribute to signaling by 
EpoR.138 However, Src kinases were dispensable for the polycythemia phenotype 
induced by JAK2 V617F, as shown by bone marrow reconstitution studies in mice 
deficient for Lyn, Fyn or Fgr kinases.139 
 
JAK2 V617F and TNF-  
In BALB/c mice reconstituted with HSCs transduced for the expression of JAK2 
V617F, the PV-like phenotype is associated with increased serum levels of TNF-
.101 TNF-  might be required for suppressing normal hematopoiesis, and in this 
manner it might favor the mutated clone. Reconstitution experiments in TNF-
knockout mice supported the notion that TNF-  might be required for the 
establishment of the MPN phenotype and for clonal dominance (Bumm TGP, 
VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, Deininger MW. TNF-
plays a crucial role in the JAK2-V617F-induced myeloproliferative 
disorder. Blood2007; 110. American Society of Hematology 2007 Abstract 675). 
Further studies will be required to firmly establish whether TNF signaling may 
contribute to clonal dominance. Erythroblasts from JAK2 V617F-positive PV patients 
show increased death receptor resistance, which may give them a proliferative 
advantage over the non-mutated erythroblasts.101, 140 This effect was mediated by 
incomplete caspase-mediated cleavage of the erythroid transcription factor GATA-1, 
which in normal erythroblasts is completely degraded on CD95 stimulation. 
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MPNs and TGF-  
An increase of TGF-  expression in circulating megakaryocytic cells and platelets 
was demonstrated in PMF.141 Fibroblasts participating in myelofibrosis were shown to 
be polyclonal, as opposed to the hematopoietic progenitors, thus suggesting that 
myelofibrosis is a reactive process.141 In myelofibrosis induced by excessive levels of 
Tpo,142 severe spleen fibrosis was seen only in wild-type mice but not in homozygous 
TGF- 1 null (TGF- 1 (-/-)) mice.143 Studies using peripheral CD34(+) cells cultured 
in medium with Tpo and stem cell factor concluded that PMF is a consequence of an 
increased ability of PMF CD34(+) progenitor cells to generate megakaryocytes and a 
decreased rate of megakaryocyte apoptosis, which lead to high levels of 
megakaryocyte-produced TGF- .144 In other models with hyperactive JAK–STAT 
signaling, such as knock-in with a mutant hyperactive gp130 receptor, the activation 
of the JAK–STAT pathway led to the expression of the inhibitory Smad7, which 
prevents the anti-proliferative effect of TGF- .145 A pathway linking Tpo, GATA-1 
and TGF- in the development of myelofibrosis was invoked, given that mice 
expressing low levels of the transcription factor GATA-1 also develop 
myelofibrosis.146 
 
 
JAK2 V617F AND CHROMATIN 
Studies in Drosophila melanogaster show that persistent activation of D-STAT by 
mutated D-JAK leads to chromatin effects and gene induction other than the normal 
targets of D-STAT, with counteracting heterochromatic gene silencing.147 A genome-
wide survey of genes required for JAK/STAT activity identified a WD40/ 
bromodomain protein Drosophila homolog of BRWD3,148 a gene that is disrupted in 
human B-cell leukemia patients. Whether any histone acetylase, deacetylase, 
methyl-transferase or other proteins containing bromo-, chromo- or chromoshadow 
domains are direct targets of JAK2 V617F is not clear. Recently, encouraging results 
were obtained with an HDAC (histone deacetylase) inhibitor, which seems to target 
only JAK2 V617F-positive cells among primary myeloid progenitors from PV 
patients.149 Thus, like other cancers,150 MPNs might also show restriction of fate 
options through hypermethylation. This notion is supported by the different effects of 
sequential treatment with the DNA methyltransferase inhibitor, decitabine, followed 
by the histone deacetylase inhibitor, trichostatin A (TSA), on normal CD34(+) versus 
PMF CD34(+) cells. In the former, the treatment led to the expansion of cells, 
whereas in the latter the total number of CD34(+) cells and hematopoietic cells was 
reduced.151  Furthermore, promoter de-methylation appears to be at least partially at 
the basis of the dysregulated expression of the polycythemia rubra vera-1 (PRV-1) 
protein,152 which is a key marker of PV.153 Finally, hypermethylation of the SOCS1 
promoter was reported approximately in 15% of MPN patients irrespective 
of JAK2 V617F positivity.154 SOCS1 promoter methylation may contribute to growth 
factor hypersensitivity, as SOCS1 appears to maintain the ability to down-modulate 
JAK2 V617F signaling.124 
Recently, Dawson et al.155 identified a novel nuclear role of JAK2 in the 
phosphorylation of Tyr 41 of histone H3 leading to chromatin displacement of HP1a. 
The authors suggested that the inability of HP1a to regulate chromatin could reduce 
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the potential tumor suppressive functions of HP1a resulting in erratic mitotic 
recombination and transcription deregulation of several JAK2-regulated genes such 
as LMO2 155,156. These results were confirmed in hematopoietic cell lines and in the 
CD34+ cells collected from the peripheral blood of one PMF patient with JAK2V617F 
mutation.  
In this work we define the subcellular localization of JAK2 in total BM cells and in 
sorted cell populations collected from MPN (ET, PV, PMF) patients with the 
JAK2V617F mutation or from MPN patients with wild type (wt) JAK2. We find that in 
contrast to cells with normal JAK2 in which the protein is detected predominantly in 
the cytoplasm, JAK2 is mostly nuclear in V617F-positive CD34+ cells. However, this 
nuclear localization is no longer observed in V617F-positive differentiated cells. After 
expressing JAK2V617F in K562 cells, we observe a similar preferential accumulation 
of JAK2 in the nucleus in contrast to untrasfected- and wt JAK2-expressing cells in 
which the protein is found in the cytoplasm. The mutated-JAK2 nuclear translocation 
is mainly reverted by the addiction of the JAK2 inhibitor AG490.  
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METHODS 
 
Cell cultures. K562 were grown in RPMI 1640 medium (Sigma-Aldrich), 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 
1% glutamine. The cells were maintained at 37 C and 5% CO2. Transfection was 
performed by AMAXA electroporation in accordance with the manufacturer’s 
instructions. Stable cell lines were obtained by puromycin selection (3µg/ml). 
Leptomycine B was added to a final concentration of 1 uM and the cells were 
harvested after 24 h of incubation. The differentiation of K562 cells was obtained by 
culturing the cells with 10 nMol PMA.   
Plasmids. pMSCV-puro-JAK2 and pMSCV-puro-JAK2V617F were kindly 
provided by Dr. J. Cools.  
Confocal immunofluorescence (CFI) microscopy. The BM fractions of CD34+, 
CD15+, CD41+, CD71+ cells and the K562 cells were washed once in PBS before 
cytocentrifugation onto polylysine-coated microscope slides. The cells were fixed for 
5 min in methanol at room temperature and 5 min in acetone at -20 C. After stepwise 
incubation with a primary antibody and a secondary fluorescent antibody, the cells 
were stained with DAPI and mounted with glycerol. Confocal laser images were 
captured with a laser scanning microscope LSM 510 META microscope equipped 
with a 403 oil-immersion lens.  
Patients. BM aspirates and PB samples were obtained from 15 patients newly 
diagnosed with MPN according to the WHO criteria. Ten of the patients (ET n=4, PV 
n=3, PMF n=3) had the V617F mutation.  The remaining 5 patients (PMF n= 2, ET 
n=3) had a normal JAK2. Informed consent for the study was obtained from all 
patients in accordance with the Declaration of Helsinki. The study was conducted 
according to the guidelines of the Italian ethics committee. 
Cell sorting. Mononucleated cells were isolated by Ficoll centrifugation. After 
erythrocyte lyses, 10 million BM (or PB) cells were labelled by incubation with the 
antibodies CD15-APC, CD41-FITC, CD71-PerCP, CD34-Pe (BD Biosciences, San 
Jose, CA), analyzed, and sorted with a fluorescence-activated cell sorter FACSAria 
(BD Biosciences) using FACS Diva software (BD Biosciences) according to the 
manufacturer’s recommendations.  
ASO-PCR and RT-PCR.  The JAK2V617F mutation was identified by ASO-PCR 
as previously described13-15. Briefly, total RNA was isolated with the TRIzol reagent 
(Invitrogen) and cDNA was synthesised with the First Strand cDNA Synthesis kit 
(MBI Fermentas). Syber Green RQ-PCR was performed as previously described155. 
Quantitative values were obtained from the threshold cycle number (Ct) by 
subtracting the average Ct of the target gene from that of GAPDH and expressed as 
2–ΔCt. 
Cell fractionation and immunoblotting. Cytoplasmic and nuclear fractions were 
prepared using nuclei isolation KIT by Sigma-Aldrich according to the manufacturer’s 
instructions.  Equal amounts of cytoplasmic or nuclear fractions or total cell extracts 
were separated by SDS–PAGE, transferred to nitrocellulose and probed with relevant 
antibodies. 
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JAK2 inhibitor and antibodies. AG490 was provided by Invivogen. To establish 
the best experimental condition, the cells were cultured for 3 hours with 2 different 
concentrations of the inhibitor (12.5 uM and 25 uM). The following antibodies were 
used at the stated dilutions: anti-JAK2 antibodies (D2E12 no. 3230; Cell Signaling 
Technology), p-JAK2 (tyr1007/tyr1008)-R and p-JAK2 (tyr1007/tyr1008) (Santa 
Cruz),anti-b-tubulin (T5201; Sigma-Aldrich), anti-laminin A (Sigma-Aldrich); western 
blot 1:1000. Alex Fluor-488-conjugated IgG (Invitrogen) immunofluorescence 1:250. 
Apoptotic rate. K562 cells were stained with propidium iodide and annexin V 
before and after 3 h incubation with AG490. Cell cycle parameters were assessed by 
FACS analysis using FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA, 
USA). 
Statistical analysis. Student t test was used to evaluate individual differences 
between means. P≤0.05 was considered significant. 
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RESULTS AND DISCUSSION 
 
V617FJAK2 goes into the nucleus of JAK2 mutated K562 
 
To determine whether the V617F mutation affects the sub-cellular localization of 
JAK2, we used CIF microscopy to analyze K562 cells stably transfected with 
pMSCV-puroJAK2V617F or pMSCV-puroJAK2. The results (Figure 1A) confirm the 
nuclear and cytoplasmic localization of JAK2 in K562 as reported by Dawson et al 155. 
However, we consistently observed a much stronger nuclear signal in the cells 
expressing JAK2V617F than in those carrying wt JAK2, suggesting that the mutation 
leads to a nuclear accumulation of JAK2V617F. By CIF, this accumulation can be 
seen as a diffused nuclear pattern (Figure 1A top, upper and middle panels) or as 
nuclear spots (Figure 1A top, lower panel). This altered sub-cellular distribution was 
not affected by the addition of the nuclear export inhibitor leptomycin B (data not 
shown) and was confirmed by Western blot analysis of K562 cells (Figure 1A, bottom 
panels).  
 
Preferential nuclear JAK2 in V617FJAK2 positive CD34+ but not in 
differentiated erythroid, granulocytic or megakaryocytic cells.  
 
To determine whether there is a preferential nuclear translocation of JAK2V617F 
in vivo, we analyzed by CIF microscopy the BM cells of 10 JAK2V617F-positive MPN 
patients (ET n=4, PV n=3, PMF n=3, allele burden median: 56%, 70%, 72% 
respectively) and of 5 MPN patients with wt JAK2 (PMF n= 2, ET n=3). We did not 
observe a significant signal in the nucleus of cells with wt JAK2 (Figure 1B). In 
contrast, we found a strong nuclear signal in 3%-5% of total BM mononucleated cells 
in 10 of 10 JAK2V617F-positive patients, suggesting that, unlike the wt JAK2, 
JAK2V617F has a predominantly nuclear homing. To identify the phenotype of these 
cells, we used fluorescence activated cell sorting (FACS) to isolate CD34+, CD15+, 
CD41+ and CD71+ fractions from the BM of three JAK2V617F-positive MPN patients 
(1 ET, 1 PV, 1 early PMF). We found nuclear JAK2 only in the fraction containing the 
CD34+ positive cells (Figure 1C, left panels). It should be noted that in these patients 
the CD34+ cells correspond to approximately 3% to 5% of total BM mononucleated 
cells. The nuclear localization of JAK2V617F was confirmed by WB analysis (Figure 
1C, right panels). However, no predominant nuclear signal was detected in 
differentiated granulocytic, megakaryocytic and erythroid cells obtained from the 
patients (n=15) (Figure 1D). Similar results were obtained with PB cells (data not 
shown).  The relocation of the mutated JAK2 to the cytoplasm was confirmed in K562 
cells after their differentiation with PMA (Figure 2A). However, the relocation was not 
complete as observed for the primary BM cells and nuclear JAK2 was still observed. 
We believe that this is due to the nature of K562 cells, which are BCR-ABL-positive 
CML cells, and to the difficulty to obtain their terminal differentiation in vitro.  
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The JAK2 inhibitor AG490 relocate JAK2 in cytoplasm 
 
To determine whether an alteration of JAK2 activity could interfere with the 
nuclear localization of JAK2, we incubated K562 cells expressing JAK2V617F or 
JAK2 with the selective JAK2 inhibitor AG490158-160. After 3 h of incubation at the 
IC50 dose of 25 uM, CIF images showed a relocalization of JAK2V617F to the 
cytoplasm in the vast majority of K562 cells (Figure 2B). Analyses with annexin V and 
propidium iodide did not reveal any significant change in the apoptotic rate of V617F-
positive and wt-K562 cells.  
 
V617F JAK2 up-regulates LMO2 and AG490 restores its level.  
 
By QRT-PCR we show that the V617F mutation strongly up-regulates the 
expression of LMO2 in K562 and in CD34+ cells (Figure 2C, left panels). The link 
between LMO2 expression and JAK2 inhibition has been reported previously156,157. In 
our assay, the addition of AG490 progressively and completely restore LMO2 levels 
in V617F expressing K562 (Figure 2C, right panels).    
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CONCLUSIONS 
 
Where do the major advances towards understanding the precise molecular 
bases of MPNs lead us? One striking observation is the key role played by various 
tyrosine kinases, constitutively activated either by balanced translocations or 
deletions generating fusion oncoproteins, or by activating point mutations. These 
mechanisms seem to be the molecular hallmark of MPNs, although there are 
probably alternative mechanisms directly involving cytokine receptors, adaptor 
proteins or transcription factors. All the molecular defects identified in MPNs to date 
confer proliferation and survival advantages on transformed cells, which retain the 
capacity to differentiate into mature cells. Differentiation may be disrupted by 
additional events, such as transcription factor deregulation, as frequently observed in 
acute myeloid leukaemia. KIT mutations and FLT3 abnormalities are frequently found 
in cases of acute myeloid leukaemia. However, these molecular defects are now 
considered to be secondary events.  
Strikingly, the diverse mutants and fusion proteins with constitutive tyrosine 
kinase activity each appear to stimulate a specific lineage. For example, PDGFR 
fusion proteins induce eosinophil differentiation, FGFR fusion proteins induce 
lymphoid malignancies, and JAK2V617F mostly expands the erythroid compartment, 
whereas translocations involving the JAK2 kinase domain promote lymphoid 
proliferation as well. Thus, constitutive signalling via these different kinases is likely 
to result in effects on specific differentiation programs. Uncovering the molecular 
details of this specificity remains a major challenge, particularly as similar signalling 
molecules (i.e. STAT5, STAT3, RAS/MAPK, PI3K/AKT and others) are constitutively 
activated by all oncogenic fusion proteins. 
Although the discovery of the JAK2V617F allele and the subsequent discovery of 
JAK2 exon 12 mutations and MPLW515L/K alleles have provided crucial insights into 
the genetic basis of PV, ET and PMF, many questions remain regarding the 
molecular pathogenesis of these MPNs. The activating mutations that cause JAK2 
and MPL-negative MPN are not known, and the inherited and acquired alleles that 
can cooperate with JAK2V617F remain to be identified. In addition, the 
predominance of the JAK2V617F allele is surprising given that JAK2 exon 12 
mutations, as well as activating JAK2 alleles identified in AML (JAK2T875N and 
JAK2ΔIREED), have similar in vitro and in vivo effects as JAK2V617F. The different 
JAK2 alleles might differentially interact with different cytokine receptor scaffolds, 
activate different signalling pathways, and/or be differentially affected by negative-
feedback mechanisms; structural insight and additional in vitro and in vivo studies are 
needed to elucidate differences between JAK2V617F and the other activating JAK2 
alleles. Another important question relates to the effects of JAK2V617F gene dosage 
on signalling and on phenotype. In vitro studies do not conclusively show whether the 
co-expression of wildtype JAK2 with JAK2V617F alters the signalling and/or 
transforming properties of the JAK2V617F kinase, and although retroviral models 
allow for an assessment of the in vivo effects of JAK2V617F expression, they do not 
provide the appropriate genetic context to investigate the importance of JAK2V617F 
gene dosage. Subsequent studies using more accurate genetic models will enable 
the delineation of the differential effects of JAK2V617F heterozygosity and 
homozygosity on signalling and on phenotype. Moreover, the role of the JAK2V617F 
allele in three distinct disorders of the myeloid lineage is not known, and the ability of 
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different activated tyrosine kinases (for example, BCR-ABL and FIP1L1–PDGFRA) to 
cause distinct MPN remains to be delineated.  
Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the 
phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from 
chromatin and resulting in a disregulation of several JAK2-regulated genes such as 
LMO2 in haematopoietic cell lines and in one case on peripheral CD34+ cells from a 
JAK2V617F mutated PMF patient. 
Our data corroborate recently published results of a nuclear localization of JAK2 
in hematopoietic cells and they also extend these findings by showing that in all 
subtypes of MPN patients JAK2V617F accumulates in the nucleus of progenitor 
CD34+ cells while it remains mostly in the cytoplasm of their differentiated progeny. 
The chromatin alterations due to the preferential accumulation of JAK2V617F in the 
nucleus correlates with a significant increase in LMO2 expression in cell lines and in 
sorted CD34+ cells. The selective JAK2 inhibitor AG490 is able to revert nuclear 
JAK2 and normalize LMO2 levels in vitro, suggesting how the block in JAK2 nuclear 
translocation could be a new treatment strategy for JAK2 mutated patients. A 
question that remains to be answered is why mutated JAK2 is found only in the 
cytoplasm of the differentiated cells. MPN are clonal disorders arising in a pluripotent 
hematopoietic stem cell and it is well known that the constitutive activation of JAK2 
provides a sustained growth and survival advantage to the hematopoietic mutated 
stem cell clones. Signaling by the mutated kinase utilizes normal pathways, and 
normal or mutated JAK2 regulate EPO, TPO, and GCS-F response during 
differentiation, though they are probably not necessary to the differentiated cell. The 
signals that are required for the translocation of normal and mutated JAK2 to the 
nucleus are unknown. It is possible that the activation of the kinase by 
phosphorylation could be the first one of a number of modifications that control 
nuclear translocation, similarly to what happens to the STAT proteins. If this is true, 
then it is also possible that as the cell undergoes differentiaition these modifications 
are shut off, leaving mutated JAK2 predominantly in the cytoplasm.  
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FIGURE LEGEND 
 
Figure 1. V617F mutation favors nuclear translocation of JAK2 in K562 and 
early CD34+ progenitors isolated from BM of MPN patients.  This translocation 
is not observed in differentiated cells. 
(A) CIF microscopy images of K562 cells stably transfected with pMSCV-JAK2 
(upper panels) or pMSCV-JAK2V617F (middle and lower panels) and Western 
blotting of cytoplasmic (C) and nuclear (N) fractions confirm that JAK2V617F is more 
abundant than JAK2 in K562 nuclei. (B) CIF images of BM cells from an MPN patient 
with wt JAK2 (upper panels) and an MPN patient with JAK2V617F (lower panels) 
confirm a nuclear increase of the mutated protein. (C) Confocal IF demonstrates a 
predominantly nuclear accumulation of JAK2V617F in CD34+ cells isolated from BM 
of 1 ET, 1 PV and 1 earlyPMF (left panels) and Western blotting of cytoplasmic (C) 
and nuclear (N) extracts (right panel) confirm the data. (D) Confocal IF images  of 
CD15+, CD41+, CD71+ cells isolated from a JAK2V617F–positive MPN patient (PV, 
JAK2 allele burden 71%) and Western blotting of cytoplasmic (C) and nuclear (N) 
extracts (right panel). DAPI, 4,6-diamidino-2-phenylindole; Anti-JAK2, Cell Signaling 
monoclonal antibody; Anti-Tubulin and Anti-Laminin A, Sigma-Aldrich monoclonal 
antibodies . 
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Figure 2. V617F mutation causes up-regulation of LMO2. The JAK2 inhibitor 
AG490 replaces JAK2 into cytoplasm and restores LMO2 levels. 
(A) Confocal IF images show the redistribution of JAK2 and the replacement in the 
cytoplasm in V617F expressing K562 after PMA differentiation (B) Confocal IF 
images show the redistribution of JAK2 and the replacement in the cytoplasm in the 
vast majority of  V617F expressing K562 (bottom panels)  but not in wt cells (top 
panels) after AG490 incubation. (C) Quantitative RT-PCR revels that V617F mutation 
strongly up-regulates LMO2 expression in K562 and in CD34+ cells (left panels). The 
addiction of AG490 progressively and completely restore LMO2 levels in V617F 
expressing K562 (right panels).  DAPI, 4,6-diamidino-2-phenylindole; Anti-JAK2, Cell 
Signaling monoclonal antibody. 
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